Corticosteroid-dependent, aldosterone-independent mineralocorticoid- receptor activation in the heart

Journal of Hypertension

Volumn 26, Issue 7, 2008, Pages 1307-1309

  Van Den Meiracker, Anton H ^a   Batenburg, Wendy W ^a  

^a ERASMUS MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

11BETA HYDROXYSTEROID DEHYDROGENASE 2; ALDOSTERONE; ALLOPURINOL; ALPHA TOCOPHEROL; ANGIOTENSIN II; CORTICOSTEROID; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; EPLERENONE; MINERALOCORTICOID RECEPTOR; OXIPURINOL; SPIRONOLACTONE; XANTHINE OXIDASE;

BLOOD PRESSURE MEASUREMENT; DISEASE COURSE; EDITORIAL; ENZYME ACTIVITY; GENE TARGETING; HEART; HEART LEFT VENTRICLE FAILURE; HUMAN; NONHUMAN; OUTCOME ASSESSMENT; OXIDATIVE STRESS; PATHOPHYSIOLOGY; PRIORITY JOURNAL; SALT INTAKE; SALT LOADING; VASCULAR SMOOTH MUSCLE; VITAMIN SUPPLEMENTATION; ANIMAL; NOTE; PHYSIOLOGY; RAT;

ADRENAL CORTEX HORMONES; ALDOSTERONE; ANIMALS; HEART; HUMANS; RATS; RECEPTORS, MINERALOCORTICOID;

EID: 54449088788     PISSN: 02636352     EISSN: None     Source Type: Journal    
DOI: 10.1097/HJH.0b013e328305e195     Document Type: Editorial

References (17)

1. Lombes M, Oblin ME, Gasc JM, Baulieu EE, Farman EE, Bonvalet JP. Immunohistochemical and biochemical evidence for a cardiovascular mineralocorticoid receptor. Circ Res 1992;71:503-510.
2. Funder JW, Myles K. Exclusion of corticosterone from epithelial mineralocorticoid receptors is insufficient for selectivity of aldosterone action: in vivo binding studies. Endocrinology 1996;137:5264.
3. Frey FJ, Odermatt A, Frey BM. Glucocorticoid-mediated mineralocorticoid receptor activation and hypertension. Curr Opin Nephrol Hypertens 2004;13:451-458.
4. Nagase M, Matsui H, Shibata S, GotodaT, Fujita T. Salt-induced nephropathy in obese spontaneously hypertensive rats via paradoxical activation of the mineralocorticoid receptor. Hypertension 2007;50:877-883.
5. Nagata K, Obata K, Xu J, Ichihara S, Noda A, Kimata H, et al. Mineralocorticoid antagonism attenuates cardiac hypertrophy and failure in low-aldosterone hypertensive rats. Hypertension 2006;47:656-664.
6. Wang H, Shimosawa T, Matsui H, Kaneko T, Ogura S, Uetake, et al. Paradoxical mineralocorticoid receptor activation and left ventricular diastolic dysfunction under high oxidative stress conditions. JHypertension 2008;26:1450-1459.
7. Griendling KK, Sorescu D, Ushio-Fukai M. NAD(P)H oxidase: role in cardiovascular biology and disease. Circ Res 2000;86:494-501.
8. Yamamuro M, Yoshimura M, Nakayama M, Abe K, Shono M, Suzuki S. Directeffects of aldosterone on cardiomyocytes in the presence of normal and elevated extracellular sodium. Endocrinology2006;147:1314-1321.
9. Ferrari P, Sansonnens A, Dick B, Frey FJ. In vivo 11. b-HSD-2. activity: variability, salt-sensitivity, and effect of licorice. Hypertension 2001;38:1330-1336.
10. Funder JW. RALES, EPHUSUS and redox. J Steroid Biochem Mol Biol 2004;93:121-125.
11. Pitt B, Remme W, Zannad F, Cody R, Castaigne A, Perez A, etal. The effect of spironolactone on morbidity and mortality in patients with severe heart failure. N Engl J Med 1999;341:709-717.
12. Pitt B, Remme W, Zannad F, Neaton J, Martinez F, Roniker B, et al. Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction. N Engl J Med 2003;348:1309-1321.
13. Jha P, Flather M, Lonn E, Farkouh M, Yusuf S. The antioxidant vitamins and cardiovascular disease: a critical review of epidemiologic and clinical trial data. Ann Intern Med 1995;123:860-872.
14. The Heart Outcomes Prevention Evaluation Study Investigators. Vitamin E supplementation and cardiovascular events in high-risk patients. N Engl J Med 2003;342:154-160.
15. The HOPE and HOPE-TOO Trial Investigators. Effects of long-term Vitamin E supplementation on cardiovascular events and cancer. A randomized controlled trial. JAMA 2005;293:1338-1347.
16. Gavin AD, Struthers AD. Allopurinol reduces B-type natriuretic peptide concentrations and haemoglobin but does not alter exercise capacity in chronic heart failure. Heart 2005;91.:749-753.
17. Reyes AJ, Leary WP. Allopurinol or oxypurinol in heart failure therapy-apromising new development of end of story? Cardiovasc Drugs Ther 2005;19:311-313.